%0 Journal Article
%T Implementing tumor mutational burden (TMB) analysis in routine diagnostics¡ªa primer for molecular pathologists and clinicians
%A Albrecht Stenzinger
%A Amelie Lier
%A Anna-Lena Volckmar
%A Eugen Rempel
%A Jan Budczies
%A Jonas Leichsenring
%A Martina Kirchner
%A Michael Allg£¿uer
%A Michael Thomas
%A Moritz von Winterfeld
%A Olaf Neumann
%A Peter Schirmacher
%A Petros Christopoulos
%A Roland Penzel
%A Stefan Fr£¿hling
%A Volker Endris
%J SCIE-indexed Journal
%D 2018
%X Tumor mutational burden (TMB) is emerging as new predictive biomarker to select patients that benefit from immune checkpoint inhibitor therapy (1-7). It is commonly defined as the total number of somatic coding mutations and associated with the emergence of neoantigens that trigger anti-tumor immunity (8-10). As a defense mechanism, tumors acquire expression of checkpoint regulators, like programmed death-ligand 1 (PD-L1), the action of which can be overcome in clinical practice with therapeutic antibodies against PD-1 (programmed cell death protein 1) or PD-L1 alone or in combination with CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) inhibitors or chemotherapy or more recently small-molecule kinase inhibitors (11-13). In numerous clinical trials over the past few years (14-21), these therapies have demonstrated impressive anti-tumor activity and are already approved for a large number of tumor entities in various indications (22) including non-small cell lung cancer (NSCLC) (23,24). Up to now, patient selection for immuno-oncologic (IO) treatment has been mainly based on expression of PD-L1 as assessed by immunohistochemistry (25,26). However, accumulating data suggest a much greater utility of TMB for this purpose
%U http://tlcr.amegroups.com/article/view/23935/18849